Faron Pharmaceuticals (AIM: FARN; First North: FARON) announced a poster presentation highlighting biological evidence from the BEXMAB Phase 1/2 trial validating its first-in-class immunotherapy candidate, bexmarilimab, for myeloid malignancies, at the European Hematology Association (EHA) 2026 Congress, June 11-14, in Stockholm.
In a statement, Dr. Mika Kontro, MD, PhD, associate professor at Helsinki University Hospital Comprehensive Cancer Center, and principal investigator of the BEXMAB trial, commented, “These results reinforce the potential of bexmarilimab to deliver clinically meaningful benefit in HR-MDS. A median duration of CR of 16.1 months in frontline patients is an encouraging signal, and the translational data add important biological depth. We are seeing evidence of genuine immune reprogramming in the bone marrow, with recovery of healthy progenitor cells and activation of cytotoxic T cell responses. Together, these findings provide a compelling foundation for the randomized Phase 2b BEXERA trial.”
Dr. Juho Jalkanen, CEO of Faron, remarked, “The findings presented at EHA 2026 represent a vital milestone in our disciplined generation of evidence for bexmarilimab. The biological evidence of hematological recovery seen with bexmarilimab means that it reduces cancer cells and actively helps a patient’s body rebuild its blood-producing system and capacity to fight the disease, providing hope for a durable recovery where options have been historically limited.”
